This study demonstrates that NAD+-induced differential expression of Eva1c/EVA1C isoforms and events downstream of EVA1C contribute to NAD+’s neurological benefits in experimental models of AD-like tauopathies. This evidence concerns the gene EVA1C and Alzheimer disease.